Founder Directory
Built by Keitoto
Founders3
Known for these resultsRole0%Role is parsed from founder titles in yc.db. Known for 0% of these rows — the rest have no title at all, mostly 2019–2023. Those rows stay in the result and are counted as Unknown, never as No.Bio100%Bio coverage: 100% of these founders have a bio on their YC profile. Every bio-derived facet (ex-company, school, credentials, discipline) is Unknown for the rest.Ex-company0%Ex-company is matched from bios with employment context (ex-, formerly, worked at). 0% of these rows have at least one match.School100%School is matched from bios, case-sensitive for acronyms. 100% of these rows have at least one match.
- Alla ArzumanyanFounder · SFA TherapeuticsS21Healthcare · Philadelphia
- Ira SpectorFounder · SFA TherapeuticsS21Healthcare · Philadelphia
- Mark Feitelson@feitelsonFounder · SFA TherapeuticsS21Healthcare · Philadelphia
FOUNDERROLEBATCHINDUSTRYLOCATIONTEAMX_url
Alla ArzumanyanSFA TherapeuticsFounderSummer 2021HealthcarePhiladelphia, United States4—Ira SpectorSFA TherapeuticsFounderSummer 2021HealthcarePhiladelphia, United States4—Mark FeitelsonSFA TherapeuticsFounderSummer 2021HealthcarePhiladelphia, United States4https://x.com/feitelson
Showing 1–3 of 3 founders
Mark Feitelson
Founder·SFA Therapeutics
PRIMARY INFO
RoleFounder· not in title
Team size4
BatchSummer 2021
LocationPhiladelphia, United States
Company statusActive
StageEarly
BIO
Mark Feitelson received his Ph.D. in Microbiology/Immunology from UCLA. He began his work with hepatitis B at Stanford University, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, Dr. Feitelson moved to Thomas Jefferson University, and in 2007, to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations. He has more than 150 publications and 180 abstracts. He is also CSO of SFA Therapeutics.
Ex-company, school and discipline below are derived from this bio. Nothing is inferred when the bio is missing.
BACKGROUND
CredentialsPhD
DisciplineResearcherKeyword match from the bio text, not a classifier.
TRACK RECORD
First YC company on record
COMPANY CONTEXT
SFA TherapeuticsRegulating the immune system to block cancer & autoimmune diseases
IndustryHealthcare
Websitesfatherapeutics.com/
Team size4
LocationPhiladelphia, United States
BatchSummer 2021
